The success of Sildenafil initially drove a period of growth for major pharmaceutical companies, but recent developments present a uncertain scenario for shareholders. Off-patent versions are eroding earnings, and https://jonasvapx895640.ttblogs.com/21106874/viagra-and-the-pharmaceutical-industry-a-precarious-bet